Studies, including ours, provided compelling evidence that such ROS-generating agents, produce oxidized phospholipid mediators, PAF, and PAF-like agonists, which bind to and activate a G-protein coupled PAFR, expressed on a variety of cell types, including tumor cells [8, 9, 22–24]. This evidence concerns the gene PCLAF and neoplasm.